Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors
Publication
, Conference
Vredenburgh, JJ; Reardon, D; Akabani, G; Friedman, A; Friedman, H; McLendon, R; Quinn, J; Rich, J; Zalutsky, M; Bigner, D
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2005
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2005
Volume
23
Issue
16
Start / End Page
116S / 116S
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
41st Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J. J., Reardon, D., Akabani, G., Friedman, A., Friedman, H., McLendon, R., … Bigner, D. (2005). Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 23, pp. 116S-116S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
Vredenburgh, J. J., D. Reardon, G. Akabani, A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, M. Zalutsky, and D. Bigner. “Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.” In JOURNAL OF CLINICAL ONCOLOGY, 23:116S-116S. AMER SOC CLINICAL ONCOLOGY, 2005.
Vredenburgh JJ, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, et al. Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2005. p. 116S-116S.
Vredenburgh, J. J., et al. “Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 16, AMER SOC CLINICAL ONCOLOGY, 2005, pp. 116S-116S.
Vredenburgh JJ, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Zalutsky M, Bigner D. Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2005. p. 116S-116S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2005
Volume
23
Issue
16
Start / End Page
116S / 116S
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
41st Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences